These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 34858732)

  • 1. CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation.
    Reyes RM; Zhang C; Deng Y; Ji N; Mukherjee N; Padron AS; Clark CA; Svatek RS; Curiel TJ
    Oncoimmunology; 2021; 10(1):2006529. PubMed ID: 34858732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
    Reyes RM; Deng Y; Zhang D; Ji N; Mukherjee N; Wheeler K; Gupta HB; Padron AS; Kancharla A; Zhang C; Garcia M; Kornepati AVR; Boyman O; Conejo-Garcia JR; Svatek RS; Curiel TJ
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
    Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro modelling of local gene therapy with IL-15/IL-15Rα and a PD-L1 antagonist in melanoma reveals an interplay between NK cells and CD4
    Awad RM; De Vlaeminck Y; Meeus F; Ertveldt T; Zeven K; Ceuppens H; Goyvaerts C; Verdonck M; Salguero G; Raes G; Devoogdt N; Breckpot K
    Sci Rep; 2023 Nov; 13(1):18995. PubMed ID: 37923822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
    Drerup JM; Deng Y; Pandeswara SL; Padrón ÁS; Reyes RM; Zhang X; Mendez J; Liu A; Clark CA; Chen W; Conejo-Garcia JR; Hurez V; Gupta H; Curiel TJ
    Cancer Res; 2020 Nov; 80(22):5063-5075. PubMed ID: 32948605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination treatment with hypofractionated radiotherapy plus IL-2/anti-IL-2 complexes and its theranostic evaluation.
    Jing H; Hettich M; Gaedicke S; Firat E; Bartholomä M; Niedermann G
    J Immunother Cancer; 2019 Feb; 7(1):55. PubMed ID: 30808414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18.
    Ma Z; Li W; Yoshiya S; Xu Y; Hata M; El-Darawish Y; Markova T; Yamanishi K; Yamanishi H; Tahara H; Tanaka Y; Okamura H
    Clin Cancer Res; 2016 Jun; 22(12):2969-80. PubMed ID: 26755531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of cancer vaccine with CD122-biased IL-2/anti-IL-2 Ab complex shapes the stem-like effector NK and CD8
    Shimizu K; Ueda S; Kawamura M; Aoshima H; Satoh M; Nakabayashi J; Fujii SI
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37400134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice.
    Hu Z; Ye L; Xing Y; Hu J; Xi T
    Sci Rep; 2018 Jan; 8(1):217. PubMed ID: 29317734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
    Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
    Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
    Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
    Front Immunol; 2020; 11():7. PubMed ID: 32117218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a
    Ren J; Xu M; Chen J; Ding J; Wang P; Huo L; Li F; Liu Z
    Theranostics; 2021; 11(1):304-315. PubMed ID: 33391476
    [No Abstract]   [Full Text] [Related]  

  • 15. Production and characterization of tumor infiltrating lymphocyte clones derived from B16-F10 murine melanoma.
    Maeda K; Lafreniere R; Jerry LM
    J Invest Dermatol; 1991 Aug; 97(2):183-9. PubMed ID: 2071934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines.
    Ji S; Lee J; Lee ES; Kim DH; Sin JI
    Hum Vaccin Immunother; 2021 Jul; 17(7):1910-1922. PubMed ID: 33522416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice.
    Xin B; Yang M; Wu P; Du L; Deng X; Hui E; Feng GS
    Hepatology; 2022 Sep; 76(3):630-645. PubMed ID: 34860431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
    Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma.
    Kalland T
    Cancer Res; 1986 Jun; 46(6):3018-22. PubMed ID: 3486041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.